Follow the people · Insider
Nello Mainolfi
Nello Mainolfi files insider transactions with the SEC as a chief executive officer of Kymera Therapeutics (KYMR). We hold 4 disclosed purchases and sales filed since 21 August 2020, 2 of them in the last 90 days.
- Files forKYMR
- Disclosed buys and sells4 in all, 2 in the last 90 days
- Last disclosure7 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 20 August 2020 — 7 July 2026Chief Executive Officer · Kymera Therapeutics (KYMR)200 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 50,000 shares of Kymera TherapeuticsSEC Form 47 July 2026Common Stock · traded 7 July 2026 · filed 7 July 2026
- ▼ sold on the open market 50,000 shares of Kymera TherapeuticsSEC Form 47 July 2026Common Stock · traded 7 July 2026 · filed 7 July 2026
- exercised options over 45,559 shares of Kymera Therapeutics (a derivative holding)SEC Form 47 July 2026Stock Option (Right to Buy) · traded 7 July 2026 · filed 7 July 2026
- exercised options over 4,441 shares of Kymera Therapeutics (a derivative holding)SEC Form 47 July 2026Stock Option (Right to Buy) · traded 7 July 2026 · filed 7 July 2026
- exercised options over 80,000 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 1,883 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 6,626 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 24,105 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 44,050 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 3,336 shares of Kymera TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- exercised options over 80,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 1 July 2026 · filed 2 July 2026
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 429 April 2026Common Stock · traded 29 April 2026 · filed 29 April 2026
- ▼ sold on the open market 17,005 shares of Kymera TherapeuticsSEC Form 429 April 2026Common Stock · traded 29 April 2026 · filed 29 April 2026
- ▼ sold on the open market 12,059 shares of Kymera TherapeuticsSEC Form 429 April 2026Common Stock · traded 29 April 2026 · filed 29 April 2026
- ▼ sold on the open market 936 shares of Kymera TherapeuticsSEC Form 429 April 2026Common Stock · traded 29 April 2026 · filed 29 April 2026
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 429 April 2026Stock Option (Right to Buy) · traded 29 April 2026 · filed 29 April 2026
- was granted 215,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- was granted 215,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 19,764 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 5,434 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 425 February 2026Stock Option (Right to Buy) · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 3,293 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 1,501 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 8 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 425 February 2026Stock Option (Right to Buy) · traded 25 February 2026 · filed 25 February 2026
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 19,764 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 5,434 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 3,293 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 1,501 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- ▼ sold on the open market 8 shares of Kymera TherapeuticsSEC Form 425 February 2026Common Stock · traded 25 February 2026 · filed 25 February 2026
- exercised options over 3,118 shares of Kymera TherapeuticsSEC Form 46 January 2026Common Stock · traded 5 January 2026 · filed 6 January 2026
- exercised options over 3,118 shares of Kymera Therapeutics (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 5 January 2026 · filed 6 January 2026
- exercised options over 3,118 shares of Kymera Therapeutics (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 5 January 2026 · filed 6 January 2026
- exercised options over 3,118 shares of Kymera TherapeuticsSEC Form 46 January 2026Common Stock · traded 5 January 2026 · filed 6 January 2026
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 431 December 2025Stock Option (Right to Buy) · traded 31 December 2025 · filed 31 December 2025
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 431 December 2025Common Stock · traded 31 December 2025 · filed 31 December 2025
- ▼ sold on the open market 23,986 shares of Kymera TherapeuticsSEC Form 431 December 2025Common Stock · traded 31 December 2025 · filed 31 December 2025
- ▼ sold on the open market 6,014 shares of Kymera TherapeuticsSEC Form 431 December 2025Common Stock · traded 31 December 2025 · filed 31 December 2025
- exercised options over 2,595 shares of Kymera Therapeutics (a derivative holding)SEC Form 417 December 2025Stock Option (Right to Buy) · traded 17 December 2025 · filed 17 December 2025
- exercised options over 2,595 shares of Kymera TherapeuticsSEC Form 417 December 2025Common Stock · traded 17 December 2025 · filed 17 December 2025
- exercised options over 100,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 48 December 2025Stock Option (Right to Buy) · traded 8 December 2025 · filed 8 December 2025
- exercised options over 100,000 shares of Kymera TherapeuticsSEC Form 48 December 2025Common Stock · traded 8 December 2025 · filed 8 December 2025
- ▼ sold on the open market 100,000 shares of Kymera TherapeuticsSEC Form 48 December 2025Common Stock · traded 8 December 2025 · filed 8 December 2025
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 429 October 2025Stock Option (Right to Buy) · traded 29 October 2025 · filed 29 October 2025
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 429 October 2025Common Stock · traded 29 October 2025 · filed 29 October 2025
- ▼ sold on the open market 1,862 shares of Kymera TherapeuticsSEC Form 429 October 2025Common Stock · traded 29 October 2025 · filed 29 October 2025
- ▼ sold on the open market 24,511 shares of Kymera TherapeuticsSEC Form 429 October 2025Common Stock · traded 29 October 2025 · filed 29 October 2025
- ▼ sold on the open market 3,627 shares of Kymera TherapeuticsSEC Form 429 October 2025Common Stock · traded 29 October 2025 · filed 29 October 2025
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 416 September 2025Stock Option (Right to Buy) · traded 16 September 2025 · filed 16 September 2025
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 416 September 2025Common Stock · traded 16 September 2025 · filed 16 September 2025
- ▼ sold on the open market 30,000 shares of Kymera TherapeuticsSEC Form 416 September 2025Common Stock · traded 16 September 2025 · filed 16 September 2025
- exercised options over 30,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 June 2025Stock Option (Right to Buy) · traded 3 June 2025 · filed 3 June 2025
- exercised options over 30,000 shares of Kymera TherapeuticsSEC Form 43 June 2025Common Stock · traded 3 June 2025 · filed 3 June 2025
- ▼ sold on the open market 30,000 shares of Kymera TherapeuticsSEC Form 43 June 2025Common Stock · traded 3 June 2025 · filed 3 June 2025
- was granted 365,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 March 2025Stock Option (Right to Buy) · traded 3 March 2025 · filed 3 March 2025
- exercised options over 10,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 413 January 2025Stock Option (Right to Buy) · traded 10 January 2025 · filed 13 January 2025
- exercised options over 10,000 shares of Kymera TherapeuticsSEC Form 413 January 2025Common Stock · traded 10 January 2025 · filed 13 January 2025
- exercised options over 18,773 shares of Kymera Therapeutics (a derivative holding)SEC Form 41 July 2024Stock Option (Right to Buy) · traded 1 July 2024 · filed 1 July 2024
- exercised options over 18,773 shares of Kymera TherapeuticsSEC Form 41 July 2024Common Stock · traded 1 July 2024 · filed 1 July 2024
- exercised options over 14,413 shares of Kymera Therapeutics (a derivative holding)SEC Form 420 June 2024Stock Option (Right to Buy) · traded 18 June 2024 · filed 20 June 2024
- exercised options over 14,413 shares of Kymera TherapeuticsSEC Form 420 June 2024Common Stock · traded 18 June 2024 · filed 20 June 2024
- was granted 530,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 44 March 2024Stock Option (Right to Buy) · traded 1 March 2024 · filed 4 March 2024
- exercised options over 9,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 42 January 2024Stock Option (Right to Buy) · traded 2 January 2024 · filed 2 January 2024
- exercised options over 9,000 shares of Kymera TherapeuticsSEC Form 42 January 2024Common Stock · traded 2 January 2024 · filed 2 January 2024
- exercised options over 2,368 shares of Kymera Therapeutics (a derivative holding)SEC Form 46 November 2023Stock Option (Right to Buy) · traded 3 November 2023 · filed 6 November 2023
- exercised options over 17,632 shares of Kymera Therapeutics (a derivative holding)SEC Form 46 November 2023Stock Option (Right to Buy) · traded 3 November 2023 · filed 6 November 2023
- exercised options over 2,368 shares of Kymera TherapeuticsSEC Form 46 November 2023Common Stock · traded 3 November 2023 · filed 6 November 2023
- exercised options over 17,632 shares of Kymera TherapeuticsSEC Form 46 November 2023Common Stock · traded 3 November 2023 · filed 6 November 2023
- exercised options over 12,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 48 August 2023Stock Option (Right to Buy) · traded 8 August 2023 · filed 8 August 2023
- exercised options over 12,000 shares of Kymera TherapeuticsSEC Form 48 August 2023Common Stock · traded 8 August 2023 · filed 8 August 2023
- was granted 450,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 March 2023Stock Option (Right to Buy) · traded 1 March 2023 · filed 3 March 2023
- exercised options over 10,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 48 December 2022Stock Option (Right to Buy) · traded 8 December 2022 · filed 8 December 2022
- exercised options over 10,000 shares of Kymera TherapeuticsSEC Form 48 December 2022Common Stock · traded 8 December 2022 · filed 8 December 2022
- exercised options over 32,056 shares of Kymera Therapeutics (a derivative holding)SEC Form 417 October 2022Stock Option (Right to Buy) · traded 17 October 2022 · filed 17 October 2022
- exercised options over 27,676 shares of Kymera Therapeutics (a derivative holding)SEC Form 417 October 2022Stock Option (Right to Buy) · traded 17 October 2022 · filed 17 October 2022
- exercised options over 32,056 shares of Kymera TherapeuticsSEC Form 417 October 2022Common Stock · traded 17 October 2022 · filed 17 October 2022
- exercised options over 27,676 shares of Kymera TherapeuticsSEC Form 417 October 2022Common Stock · traded 17 October 2022 · filed 17 October 2022
- exercised options over 20,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 May 2022Stock Option (Right to Buy) · traded 3 May 2022 · filed 3 May 2022
- exercised options over 20,000 shares of Kymera TherapeuticsSEC Form 43 May 2022Common Stock · traded 3 May 2022 · filed 3 May 2022
- was granted 275,100 shares of Kymera Therapeutics (a derivative holding)SEC Form 43 March 2022Stock Option (Right to Buy) · traded 1 March 2022 · filed 3 March 2022
- exercised options over 10,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 414 January 2022Stock Option (Right to Buy) · traded 14 January 2022 · filed 14 January 2022
- exercised options over 10,000 shares of Kymera TherapeuticsSEC Form 414 January 2022Common Stock · traded 14 January 2022 · filed 14 January 2022
- exercised options over 22,465 shares of Kymera Therapeutics (a derivative holding)SEC Form 412 January 2022Stock Option (Right to Buy) · traded 10 January 2022 · filed 12 January 2022
- exercised options over 16,923 shares of Kymera Therapeutics (a derivative holding)SEC Form 412 January 2022Stock Option (Right to Buy) · traded 11 January 2022 · filed 12 January 2022
- exercised options over 8,612 shares of Kymera Therapeutics (a derivative holding)SEC Form 412 January 2022Stock Option (Right to Buy) · traded 12 January 2022 · filed 12 January 2022
- exercised options over 22,465 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
- ▼ sold on the open market 7,485 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
- ▼ sold on the open market 10,673 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
- ▼ sold on the open market 4,201 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
- ▼ sold on the open market 106 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
- exercised options over 16,923 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 11 January 2022 · filed 12 January 2022
- ▼ sold on the open market 9,932 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 11 January 2022 · filed 12 January 2022
- ▼ sold on the open market 6,644 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 11 January 2022 · filed 12 January 2022
- ▼ sold on the open market 347 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 11 January 2022 · filed 12 January 2022
- exercised options over 8,612 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 12 January 2022 · filed 12 January 2022
- ▼ sold on the open market 2,726 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 12 January 2022 · filed 12 January 2022
- ▼ sold on the open market 4,022 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 12 January 2022 · filed 12 January 2022
- ▼ sold on the open market 1,623 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 12 January 2022 · filed 12 January 2022
- ▼ sold on the open market 241 shares of Kymera TherapeuticsSEC Form 412 January 2022Common Stock · traded 12 January 2022 · filed 12 January 2022
- exercised options over 8,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 416 December 2021Stock Option (Right to Buy) · traded 16 December 2021 · filed 16 December 2021
- exercised options over 8,000 shares of Kymera TherapeuticsSEC Form 416 December 2021Common Stock · traded 16 December 2021 · filed 16 December 2021
- exercised options over 41,544 shares of Kymera Therapeutics (a derivative holding)SEC Form 412 October 2021Stock Option (Right to Buy) · traded 8 October 2021 · filed 12 October 2021
- exercised options over 6,456 shares of Kymera Therapeutics (a derivative holding)SEC Form 412 October 2021Stock Option (Right to Buy) · traded 11 October 2021 · filed 12 October 2021
- exercised options over 41,544 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 21,236 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 9,369 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 2,078 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 7,920 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 670 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- ▼ sold on the open market 271 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 8 October 2021 · filed 12 October 2021
- exercised options over 6,456 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 11 October 2021 · filed 12 October 2021
- ▼ sold on the open market 5,712 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 11 October 2021 · filed 12 October 2021
- ▼ sold on the open market 744 shares of Kymera TherapeuticsSEC Form 412 October 2021Common Stock · traded 11 October 2021 · filed 12 October 2021
- exercised options over 12,000 shares of Kymera Therapeutics (a derivative holding)SEC Form 419 August 2021Stock Option (Right to Buy) · traded 19 August 2021 · filed 19 August 2021
- exercised options over 12,000 shares of Kymera TherapeuticsSEC Form 419 August 2021Common Stock · traded 19 August 2021 · filed 19 August 2021
- exercised options over 5,669 shares of Kymera Therapeutics (a derivative holding)SEC Form 45 August 2021Stock Option (Right to Buy) · traded 3 August 2021 · filed 5 August 2021
- exercised options over 1,037 shares of Kymera Therapeutics (a derivative holding)SEC Form 45 August 2021Stock Option (Right to Buy) · traded 4 August 2021 · filed 5 August 2021
- exercised options over 5,669 shares of Kymera TherapeuticsSEC Form 45 August 2021Common Stock · traded 3 August 2021 · filed 5 August 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.